@kewur 1 month ago
BioNTech revenue down 60%, hit with recent clinical trial setbacks
BioNTech revenue down 60%, hit with recent clinical trial setbacks
BioNTech's Q2 revenue dropped 60% to 105.6 million euros as COVID vaccine sales decline. They also posted a net loss of 3.24 euros per share. On the clinical side, they halted a Phase 2 colorectal cancer trial in August, and their BNT113 candidate just missed a primary endpoint in a head and neck cancer trial. Stock dropped 5% on the latest news. They still have a deep oncology pipeline, but it is looking like a risky play given the $23B market cap.

www.fool.com
| Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? | The Motley Fool

There are no comments here, be the first to comment